Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + Rituximab first-line therapy in frail elderly DLBCL
2015-003371-29Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and rituximab in diffuse large B-cell lymphoma (DLBCL) and B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Overall response rate. Started Nov 2020; status: completed.
02
Drugs
lenalidomiderituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on 2015-003371-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003371-29.